Patients with CLL on continuous ibrutinib have a life expectancy comparable to healthy individuals

Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses a study showing that patients in Europe with chronic lymphocytic leukemia (CLL) treated with continuous ibrutinib have a life expectancy comparable to that of healthy individuals, regardless of age at which they are diagnosed. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.